http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
-
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
-
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
-
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
-
Exagen (XGN) Appoints John Aballi as CEO
-
Exagen Announces Appointment of John Aballi as CEO
-
Exagen Announces Appointment of John Aballi as CEO
-
Exagen Inc (XGN) Appoints Andrew L. Concoff as Chief Innovation Officer
-
Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
-
Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
-
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
-
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
-
Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
-
Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
-
Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
-
Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
-
Exagen Inc. Reports Second Quarter 2022 Results
-
Exagen Inc. Reports Second Quarter 2022 Results
-
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
-
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
-
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
-
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
-
Exagen Inc (XGN) Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
-
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
-
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
-
Exagen Inc (XGN) Expands Coverage with MediNcrease
-
Exagen Inc. Expands Coverage with MediNcrease
-
Exagen Inc. Expands Coverage with MediNcrease
-
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
-
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
-
Exagen Inc (XGN) Expands Coverage with Alivio Health
-
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
-
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
-
Exagen Inc (XGN) Announces New PLA Code and Medicare Pricing for Proprietary AVISE Lupus Test
-
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
-
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
-
Exagen Inc. Reports First Quarter 2022 Results
-
Exagen Inc. Reports First Quarter 2022 Results
-
Exagen Announces Five-Week Campaign for Lupus Awareness Month
-
Exagen Announces Five-Week Campaign for Lupus Awareness Month
-
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
-
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
-
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
-
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month

